RAPIDATA AND OTHER THINGS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 在国家同步加速器光源(NSLS)举办的大分子结晶学方法国际上最广泛认可的课程之一。自1999年以来，每年春天，来自世界各地的学生都会聚集在NSLS参加RapiData，这是一个由Sweet、Alex Soares和Sal Sclafani组织的为期一周的速成课程，是P41项目的培训部分。它的目的是向参与者介绍最好的和最新的大分子X射线结晶学设备和技术。RapiData允许学生与结晶学领域的领先软件开发人员见面并向他们学习，然后实际使用NSLS光束线来收集数据。今年，52名学生参加了4月11日至16日举行的研讨会。 自开设以来，已有近600名学生参加了这门课程，我们不断要求增加更多的名额。许多RapiData校友现在已经成长为结晶学专家，他们继续将经验较少的同事推荐到BNL，以了解这一高度专业化的感兴趣领域的初始步骤。我们经常收到以前RapiData学生的研究生。 课程从Sweet教授的为期一天的背景课程开始，旨在为经验较少的学生更新晶体基础知识。接下来的两天充满了来自BNL、工业、学术界和其他国家实验室的科学家的讲座和教程。接下来，学生们被分组，并在8条NSLS光束线上引导进行了长达60小时的马拉松式数据收集课程。与此同时，许多教程正在进行中，由讲师自己管理。近三分之二的学生带来了自己的标本，目的是解开特定酶的结构，而其他人则观察并帮助他们。在课程期间，大约解决了六个结构，每个结构都可能是一个可发布的结果。在课程的数据收集部分，学生们每天下午聚集在一起讨论他们的结果，并制作关于他们的数据和科学主题的小型讲座。 看着学生们整个星期的技能发展总是令人兴奋的。他们中的许多人来到这里时几乎没有结晶学经验，离开时他们知道如何获取和处理真实数据，以及如何在出现问题时定位和修复问题。这就是拥有这样一个动手项目的优势。 除了美国能源部和美国国立卫生研究院的资助外，国际结晶学联盟还提供了一笔特别补助金，帮助七名拉丁美洲学生参加该课程。布鲁克海文科学协会、NSLS以及几家设备供应商和制药公司提供了额外的支持。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. One of the most widely recognized courses internationally in macromolecular crystallography methods is held at the National Synchrotron Light Source (NSLS). Since 1999, students from around the world have gathered at the NSLS every spring for RapiData, a weeklong crash course organized by Sweet, Alex Soares, and Sal Sclafani, a training component of this P41 project. It's designed to introduce participants to the best and latest equipment and techniques for macromolecular x-ray crystallography. RapiData allows students to meet and learn from the leading developers of software in the crystallography field, and then to actually use NSLS beamlines to collect data. This year, 52 students attended the workshop, which was held from April 11-16. Since its creation, nearly 600 students have attended this course, and we have constant requests to add more slots. Many RapiData alumni have now blossomed into crystallography experts, and they continue to refer their less-experienced colleagues to BNL to learn the initial steps of this highly specialized area of interest. We regularly get graduate students of former RapiData students. The course began with a daylong background session taught by Sweet, meant to refresh the knowledge of crystallography fundamentals for less-experienced students. The following two days were filled with lectures and tutorials taught by scientists from BNL, industry, academia, and other national labs. Next, the students were divided into groups and guided through a marathon, 60-hour data-collection session on eight NSLS beamlines. At the same time, many tutorials were underway, run by the lecturers themselves. Nearly two-thirds of the students brought their own specimens with the goal of solving the structure of a particular enzyme, while the others observed and helped. About half a dozen structures were solved during the course, each of which could be a publishable result. During the data-collection portion of the course, the students gathered each afternoon to discuss their results and produced mini lectures about their data and scientific subject. It's always really exciting to watch the students' skills develop throughout the week. Many of them come here with little or no experience in crystallography, and they leave knowing how to obtain and process real data, as well as how to locate and fix problems as they arise. That's the advantage of having such a hands-on program. In addition to the DOE and NIH funding, a special grant was provided by the International Union for Crystallography to assist seven Latin American students in attending the course. Additional support was provided by Brookhaven Science Associates, the NSLS, and several equipment vendors and drug companies.